{"id":22614,"date":"2016-06-21T13:57:00","date_gmt":"2016-06-21T12:57:00","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=22614"},"modified":"2016-06-21T13:57:00","modified_gmt":"2016-06-21T12:57:00","slug":"actualitzacio-en-la-gestio-de-lmpoc-i-lasma","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/","title":{"rendered":"Actualizaci\u00f3n en la gesti\u00f3n de la EPOC y el asma"},"content":{"rendered":"<p>La prevalencia de la<b>EPOC<\/b> en Espa\u00f1a es del 9,1% y representa <b>la cuarta causa de mortalidad de nuestro pa\u00eds<\/b>. El humo del tabaco es el principal factor de riesgo adem\u00e1s de otros como la poluci\u00f3n, los factores gen\u00e9ticos y el d\u00e9ficit de la enzima alfa1-antitripsina. El tratamiento farmacol\u00f3gico y la educaci\u00f3n sanitaria del paciente con EPOC son una parte esencial para conseguir el \u00e9xito de la evoluci\u00f3n. Sin embargo, <b>el asma es una de las enfermedades cr\u00f3nicas m\u00e1s comunes en todo el mundo con una afectaci\u00f3n de aproximadamente 300 millones de personas<\/b>. La incidencia, la morbilidad y la mortalidad de esta enfermedad han aumentado a pesar del desarrollo de nuevos medicamentos. En los \u00faltimos tiempos han aparecido <b>novedades terap\u00e9uticas y gu\u00edas de consenso de las sociedades cient\u00edficas que han hecho replantear la estrategia del tratamiento<\/b>. Por ello es conveniente realizar una actualizaci\u00f3n de conocimientos y una revisi\u00f3n de estas patolog\u00edas y de la gesti\u00f3n del tratamiento.<\/p>\n<p><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/06\/actualitzaci\u00f3-MPOC-asma-jornada-2.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"alignright  wp-image-22622\" alt=\"actualitzaci\u00f3-MPOC-asma-jornada (2)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/06\/actualitzaci\u00f3-MPOC-asma-jornada-2-1024x663.jpg\" width=\"298\" height=\"193\" \/><\/a>Con el objetivo de ponerse al d\u00eda de las novedades en terap\u00e9utica inhalatoria en cuanto a principios activos, combinaciones y nuevos dispositivos para EPOC y asma, saber gestionar el tratamiento de los pacientes con EPOC y asma desde la atenci\u00f3n primaria, e identificar los tipos de pacientes que acuden a los servicios de neumolog\u00eda y saber cu\u00e1les son los criterios de selecci\u00f3n de los tratamientos que se prescriben con inhaladores, el COFB acogi\u00f3 una<strong> jornada de actualizaci\u00f3n y reflexi\u00f3n sobre el manejo y tratamiento de los pacientes con EPOC y asma<\/strong>, una actividad organizada conjuntamente con la <a href=\"http:\/\/www.scfarmclin.org\/\" target=\"_blank\" rel=\"noopener\">Sociedad Catalana de Farmacia Cl\u00ednica (SCFC)<\/a> y la <a href=\"http:\/\/www.sefap.org\/\">Sociedad Espa\u00f1ola de Farmac\u00e9uticos de Atenci\u00f3n Primaria (SEFAP).<\/a><\/p>\n<p>El equipo docente estuvo formado por <b>Esther Pastor<\/b>, farmac\u00e9utica de atenci\u00f3n primaria del Servicio de Atenci\u00f3n Primaria Vall\u00e8s Oriental (Instituto Catal\u00e1n de la Salud), <b>Pedro J. Simonet<\/b>, m\u00e9dico de familia del EAP Viladecans 2 del Instituto Catal\u00e1n de la Salud y miembro del grupo de Enfermedades respiratorias CAMFiC, y <b>Ingrid Solanes,<\/b> neum\u00f3loga adjunta del Servicio de Neumolog\u00eda del Hospital de la Santa Cruz y Sant Pau de Barcelona.<\/p>\n\n<p>Solanes explic\u00f3 en la jornada que en las \u00faltimas d\u00e9cadas se ha producido <b>un aumento progresivo en el inter\u00e9s en el manejo de los pacientes con EPOC<\/b>, siendo en la actualidad comparable con el del asma, lo que se ve reflejado en la cantidad de novedades terap\u00e9uticas comercializadas en los \u00faltimos seis a\u00f1os. Pastor coment\u00f3 las principales caracter\u00edsticas de estas novedades, tanto por <b>monof\u00e1rmacos <\/b>como por<b> las combinaciones<\/b>, y si aportan alg\u00fan valor a\u00f1adido o no. A continuaci\u00f3n, Simonet y Solanes dieron su<b> visi\u00f3n cl\u00ednica del diagn\u00f3stico y manejo de estos pacientes<\/b> en la Atenci\u00f3n Primaria y en la Atenci\u00f3n Especializada de Neumolog\u00eda.<\/p>\n<div class=\"box shadow\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/06\/actualitzaci\u00f3-MPOC-asma-jornada-4.jpg\"><img decoding=\"async\" class=\"wp-image-22624 alignleft\" alt=\"actualitzaci\u00f3-MPOC-asma-jornada (4)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/06\/actualitzaci\u00f3-MPOC-asma-jornada-4-1024x683.jpg\" width=\"274\" height=\"182\" \/><\/a>\u201cComo principal conclusi\u00f3n podemos decir que en los pacientes con EPOC las medidas m\u00e1s importantes para mejorar la supervivencia y calidad de vida de estos pacientes es realizar un <b>correcto diagn\u00f3stico lo antes posible<\/b> (en la enfermedad muy avanzada y con mucha sintomatolog\u00eda hay poco margen para mejorar el pron\u00f3stico) y <b>fomentar el ejercicio f\u00edsico y la deshabituaci\u00f3n tab\u00e1quica<\/b>\u201d explica <b>Roser Vall\u00e8s, vocal de Atenci\u00f3n Primaria del <\/b>COFB y una de las coordinadoras de la jornada. \u201cLos tratamientos farmacol\u00f3gicos no aumentan la supervivencia, s\u00f3lo <b>mejoran la sintomatolog\u00eda<\/b>. Las novedades terap\u00e9uticas no han demostrado superioridad a los f\u00e1rmacos inhaladores que ya ten\u00edamos disponibles para el manejo tanto del asma como de la EPOC\u201d.<\/div>\n<p>La jornada tambi\u00e9n estuvo coordinada por <b>Tom\u00e1s Casas\u00edn<\/b>, ex vocal de Hospitales del COF de Barcelona, <b>Esther Amado<\/b>, vocal en Catalu\u00f1a de la Sociedad Espa\u00f1ola de Farmac\u00e9uticos de Atenci\u00f3n Primaria (SEFAP), y <b>Julio Mart\u00ednez<\/b>, presidente de la Sociedad Catalana de Farmacia Cl\u00ednica (SCFC).<\/p>\n<p><span style=\"color: #888888;\"><strong>Esta jornada tambi\u00e9n pudo seguirse en directo mediante conexi\u00f3n Webinar (online).<\/strong><\/span><\/p>\n<p align=\"right\"><b>Con la colaboraci\u00f3n de:<\/b><\/p>\n<p align=\"right\"><a href=\"https:\/\/www.boehringer-ingelheim.es\/\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" class=\"alignright size-thumbnail wp-image-21656\" alt=\"logo-boehringeringelheim\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/logo-boehringeringelheim-150x45.jpg\" width=\"150\" height=\"45\" \/><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>La prevalencia de la EPOC en el Estado espa\u00f1ol es del 9,1% y representa la cuarta causa de mortalidad de nuestro pa\u00eds. El humo del tabaco es el principal factor de riesgo adem\u00e1s de otros como la poluci\u00f3n, los factores gen\u00e9ticos y el d\u00e9ficit de la enzima alfa1-antitripsina. El tratamiento farmacol\u00f3gico y la educaci\u00f3n [\u2026]<\/p>","protected":false},"author":1,"featured_media":22622,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[211,938,1004],"class_list":["post-22614","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-asma","tag-atencio-primaria","tag-mpoc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Actualitzaci\u00f3 en la gesti\u00f3 de l&#039;MPOC i l&#039;asma - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Actualitzaci\u00f3 en la gesti\u00f3 de l&#039;MPOC i l&#039;asma - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"La prevalen\u00e7a de l\u2019MPOC a l\u2019Estat espanyol \u00e9s del 9,1% i representa la quarta causa de mortalitat del nostre pa\u00eds. El fum del tabac n\u2019\u00e9s el principal factor de risc a m\u00e9s d\u2019altres com la pol\u00b7luci\u00f3, els factors gen\u00e8tics i el d\u00e8ficit de l\u2019enzim alfa1-antitripsina. El tractament farmacol\u00f2gic i l\u2019educaci\u00f3 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-06-21T12:57:00+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Actualitzaci\u00f3 en la gesti\u00f3 de l&#8217;MPOC i l&#8217;asma\",\"datePublished\":\"2016-06-21T12:57:00+00:00\",\"dateModified\":\"2016-06-21T12:57:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\"},\"wordCount\":709,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"asma\",\"Atenci\u00f3 prim\u00e0ria\",\"MPOC\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\",\"name\":\"Actualitzaci\u00f3 en la gesti\u00f3 de l'MPOC i l'asma - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2016-06-21T12:57:00+00:00\",\"dateModified\":\"2016-06-21T12:57:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualitzaci\u00f3 en la gesti\u00f3 de l&#8217;MPOC i l&#8217;asma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Actualitzaci\u00f3 en la gesti\u00f3 de l'MPOC i l'asma - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/","og_locale":"es_ES","og_type":"article","og_title":"Actualitzaci\u00f3 en la gesti\u00f3 de l'MPOC i l'asma - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"La prevalen\u00e7a de l\u2019MPOC a l\u2019Estat espanyol \u00e9s del 9,1% i representa la quarta causa de mortalitat del nostre pa\u00eds. El fum del tabac n\u2019\u00e9s el principal factor de risc a m\u00e9s d\u2019altres com la pol\u00b7luci\u00f3, els factors gen\u00e8tics i el d\u00e8ficit de l\u2019enzim alfa1-antitripsina. El tractament farmacol\u00f2gic i l\u2019educaci\u00f3 [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2016-06-21T12:57:00+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Actualitzaci\u00f3 en la gesti\u00f3 de l&#8217;MPOC i l&#8217;asma","datePublished":"2016-06-21T12:57:00+00:00","dateModified":"2016-06-21T12:57:00+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/"},"wordCount":709,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage"},"thumbnailUrl":"","keywords":["asma","Atenci\u00f3 prim\u00e0ria","MPOC"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/","url":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/","name":"Actualitzaci\u00f3 en la gesti\u00f3 de l'MPOC i l'asma - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage"},"thumbnailUrl":"","datePublished":"2016-06-21T12:57:00+00:00","dateModified":"2016-06-21T12:57:00+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Actualitzaci\u00f3 en la gesti\u00f3 de l&#8217;MPOC i l&#8217;asma"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"La prevalen\u00e7a de l\u2019MPOC a l\u2019Estat espanyol \u00e9s del 9,1% i representa la quarta causa de mortalitat del nostre pa\u00eds. El fum del tabac n\u2019\u00e9s el principal factor de risc a m\u00e9s d\u2019altres com la pol\u00b7luci\u00f3, els factors gen\u00e8tics i el d\u00e8ficit de l\u2019enzim alfa1-antitripsina. El tractament farmacol\u00f2gic i l\u2019educaci\u00f3 [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/22614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=22614"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/22614\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=22614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=22614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=22614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}